Bio-Rad Laboratories BIO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Clinical Diagnostics | $363.6M+1.9% | $425.3M+8.4% | $391.2M+0.6% | $388.8M+0.2% | $356.8M-3.2% | |
| Life Science | $228.5M0.0% | $267.9M-2.6% | $261.8M+0.3% | $262.8M+4.9% | $228.6M-5.4% | |
| Gross Profit by Business | ||||||
| Clinical Diagnostics | $181.8M+2.4% | $214.7M+15.6% | $197.5M-4.1% | $197M-6.4% | $177.6M-8.6% | |
| Life Science | $127.6M-0.6% | $130.5M-16.5% | $145.9M-2.7% | $148.3M+2.6% | $128.4M-2.5% | |
| Total Assets by Business | ||||||
| Clinical Diagnostics | $468.8M-2.7% | $451.4M-4.6% | $472.3M-5.5% | $489M-1.2% | $482M-2.0% | |
| Life Science | $301.7M-2.1% | $289.3M+0.9% | $310.9M+2.1% | $309.8M+0.3% | $308.1M+5.6% | |
| Cost of goods sold by Business | ||||||
| Clinical Diagnostics | $181.8M+1.5% | $210.6M+1.8% | $193.7M+6.0% | $191.8M+8.1% | $179.2M+2.8% | |
| Life Science | $100.9M+0.7% | $137.4M+15.7% | $115.9M+4.4% | $114.5M+8.1% | $100.2M-8.9% | |
| Goodwill, net by Business | ||||||
| Clinical Diagnostics | $128.4M+4.3% | $128.4M+7.9% | $127.5M+3.2% | $128.2M+6.3% | $123.1M+1.5% | |
| Life Science | $448.7M+53.9% | $451.4M+54.9% | $451.2M+54.8% | $453.4M+55.5% | $291.5M0.0% | |
| Depreciation, Depletion and Amortization by Business | ||||||
| Clinical Diagnostics | $22.6M+7.1% | $22.9M+5.0% | $23.6M+9.8% | $22.8M+13.4% | $21.1M+1.4% | |
| Life Science | $18.3M+7.6% | $19.6M+12.6% | $20.6M+18.4% | $17.8M+9.2% | $17M+4.3% | |
| Goodwill by Business | ||||||
| Clinical Diagnostics | $421.8M+1.3% | $421.8M+2.3% | $420.9M+0.9% | $421.6M+1.8% | $416.5M+0.4% | |
| Life Science | $490.5M+47.2% | $493.2M+48.0% | $493M+47.9% | $495.2M+48.6% | $333.3M0.0% | |
| Goodwill, Impaired, Accumulated Impairment Loss by Business | ||||||
| Clinical Diagnostics | $293.4M0.0% | $293.4M0.0% | $293.4M0.0% | $293.4M0.0% | $293.4M0.0% | |
| Life Science | $41.8M0.0% | $41.8M0.0% | $41.8M0.0% | $41.8M0.0% | $41.8M0.0% | |
| Goodwill, Period Increase (Decrease) by Business | ||||||
| Clinical Diagnostics | $0-100% | $900K+120% | $0-100% | $5.1M+829% | $4.1M+613% | |
| Life Science | -$2.7M— | $200K— | $0— | $161.9M— | $0— | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| Clinical Diagnostics | $0-100% | $900K+120% | $0-100% | $5.1M+829% | $4.1M+613% | |
| Life Science | -$2.7M— | —— | -$800K— | $0— | $0— | |
| Net Sales by Geography | ||||||
| Americas | $45.1M+13.3% | $44.7M+8.2% | $39.8M-2.7% | $41.1M-11.8% | $39.8M-1.7% | |
| Asia Pacific | $110.4M+6.1% | $161.8M+10.5% | $121M-4.6% | $126.4M-3.7% | $104.1M-11.2% | |
| Europe | $206.8M+3.5% | $242.6M+9.4% | $222.2M+8.0% | $217.2M+5.2% | $199.8M-0.2% | |
| UNITED STATES | $229.8M-4.9% | $244.1M-5.4% | $270M-2.2% | $266.9M+5.0% | $241.7M-4.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bio-Rad Laboratories break its business down?
- Bio-Rad Laboratories (BIO) reports net sales by business across 3 parts — All Other Segments, Clinical Diagnostics and Life Science. Each is extracted from the segment footnotes and tracked over time.
- Where does Bio-Rad Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bio-Rad Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
